Kokichi Honda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kokichi Honda has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Toshinori Agatsuma
Daiichi Sankyo Co., Ltd., Tokyo, Japan
29 shared publications - Yuki Abe
Daiichi Sankyo Co., Ltd., Tokyo, Japan
29 shared publications - Atsuko Takatsuka
Daiichi Sankyo Co., Ltd., Tokyo, Japan
21 shared publications - Chiemi Saito
Daiichi Sankyo Co., Ltd., Tokyo, Japan
21 shared publications - Hirokazu Suzuki
Daiichi Sankyo Co., Ltd., Tokyo, Japan
21 shared publications - Kensuke Nakamura
Modality Research Laboratories, Biologics Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan
21 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Tumor-associated mucin-1 (TA-MUC1) is a glycoform of the MUC1 protein that is aberrantly glycosylated and is primarily observed in cancer cells. TA-MUC1 is highly expressed in various human epithelial cancers, making it an attractive target for cancer therapies. In this study, we describe the development of DS-3939a, a novel TA-MUC1–targeting antibody–drug conjugate that utilizes the potent DNA topoisomerase I inhibitor DXd, and evaluation of its pharmacologic activity in preclinical in vitro and in vivo models. IHC of clinical tumor tissue microarrays of various cancer types exhibited positive staining for TA-MUC1 in a number of samples, with a particularly high positive rate in bladder, lung, and breast cancers. In vitro profiling of DS-3939a confirmed that it could specifically bind to TA-MUC1 and inhibit the growth of TA-MUC1–positive cancer cells by inducing DNA damage and apoptosis. DS-3939a also exhibited significant antitumor effects in multiple TA-MUC1–positive cell line–derived and patient-derived xenograft models. Moreover, DS-3939a elicited strong tumor regression in several xenograft models even following treatment with other cytotoxic antibody–drug conjugates, likely through its efficient payload delivery. Overall, these data provide evidence for the potential utility of DS-3939a for the treatment of TA-MUC1–expressing tumors and support the rationale for the ongoing phase I/II clinical study (NCT05875168).
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Tumor-associated mucin-1 (TA-MUC1) is a glycoform of the MUC1 protein that is aberrantly glycosylated and is primarily observed in cancer cells. TA-MUC1 is highly expressed in various human epithelial cancers, making it an attractive target for cancer therapies. In this study, we describe the development of DS-3939a, a novel TA-MUC1–targeting antibody–drug conjugate that utilizes the potent DNA topoisomerase I inhibitor DXd, and evaluation of its pharmacologic activity in preclinical in vitro and in vivo models. IHC of clinical tumor tissue microarrays of various cancer types exhibited positive staining for TA-MUC1 in a number of samples, with a particularly high positive rate in bladder, lung, and breast cancers. In vitro profiling of DS-3939a confirmed that it could specifically bind to TA-MUC1 and inhibit the growth of TA-MUC1–positive cancer cells by inducing DNA damage and apoptosis. DS-3939a also exhibited significant antitumor effects in multiple TA-MUC1–positive cell line–derived and patient-derived xenograft models. Moreover, DS-3939a elicited strong tumor regression in several xenograft models even following treatment with other cytotoxic antibody–drug conjugates, likely through its efficient payload delivery. Overall, these data provide evidence for the potential utility of DS-3939a for the treatment of TA-MUC1–expressing tumors and support the rationale for the ongoing phase I/II clinical study (NCT05875168).
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Binding activity of assay control antibodies against MUC1 peptides was evaluated by ELISA.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Binding activity of assay control antibodies against MUC1 peptides was evaluated by ELISA.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Photomicrograph of human normal tissues showing positive for TA-MUC1.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Photomicrograph of human normal tissues showing positive for TA-MUC1.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Expression level and internalization of each ADC target.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Expression level and internalization of each ADC target.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Amino acid sequences of anti-TA-MUC1 antibody.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Amino acid sequences of anti-TA-MUC1 antibody.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Representative images of human tumor tissues analyzed by IHC staining for TA-MUC1 with moderate and strong staining intensities in select cancer types.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Representative images of human tumor tissues analyzed by IHC staining for TA-MUC1 with moderate and strong staining intensities in select cancer types.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Correlation analysis of the efficacy of DS-3939a and TA-MUC1 expression in evaluated PDX models.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Correlation analysis of the efficacy of DS-3939a and TA-MUC1 expression in evaluated PDX models.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (1) , 7-20
DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Tumor-associated mucin-1 (TA-MUC1) is a glycoform of the MUC1 protein that is aberrantly glycosylated and is primarily observed in cancer cells. TA-MUC1 is highly expressed in various human epithelial cancers, making it an attractive target for cancer therapies. In this study, we describe the development of DS-3939a, a novel TA-MUC1–targeting antibody–drug conjugate that utilizes the potent DNA topoisomerase I inhibitor DXd, and evaluation of its pharmacologic activity in preclinical in vitro and in vivo models. IHC of clinical tumor tissue microarrays of various cancer types exhibited positive staining for TA-MUC1 in a number of samples, with a particularly high positive rate in bladder, lung, and breast cancers. In vitro profiling of DS-3939a confirmed that it could specifically bind to TA-MUC1 and inhibit the growth of TA-MUC1–positive cancer cells by inducing DNA damage and apoptosis. DS-3939a also exhibited significant antitumor effects in multiple TA-MUC1–positive cell line–derived and patient-derived xenograft models. Moreover, DS-3939a elicited strong tumor regression in several xenograft models even following treatment with other cytotoxic antibody–drug conjugates, likely through its efficient payload delivery. Overall, these data provide evidence for the potential utility of DS-3939a for the treatment of TA-MUC1–expressing tumors and support the rationale for the ongoing phase I/II clinical study (NCT05875168).
- 9 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (1) , 7-20
Open AccessDS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity
Tumor-associated mucin-1 (TA-MUC1) is a glycoform of the MUC1 protein that is aberrantly glycosylated and is primarily observed in cancer cells. TA-MUC1 is highly expressed in various human epithelial cancers, making it an attractive target for cancer therapies. In this study, we describe the development of DS-3939a, a novel TA-MUC1–targeting antibody–drug conjugate that utilizes the potent DNA topoisomerase I inhibitor DXd, and evaluation of its pharmacologic activity in preclinical in vitro and in vivo models. IHC of clinical tumor tissue microarrays of various cancer types exhibited positive staining for TA-MUC1 in a number of samples, with a particularly high positive rate in bladder, lung, and breast cancers. In vitro profiling of DS-3939a confirmed that it could specifically bind to TA-MUC1 and inhibit the growth of TA-MUC1–positive cancer cells by inducing DNA damage and apoptosis. DS-3939a also exhibited significant antitumor effects in multiple TA-MUC1–positive cell line–derived and patient-derived xenograft models. Moreover, DS-3939a elicited strong tumor regression in several xenograft models even following treatment with other cytotoxic antibody–drug conjugates, likely through its efficient payload delivery. Overall, these data provide evidence for the potential utility of DS-3939a for the treatment of TA-MUC1–expressing tumors and support the rationale for the ongoing phase I/II clinical study (NCT05875168).
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
The binding activities of R-DXd.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
The binding activities of R-DXd.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Table S3. from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
Concentration of sCDH6 in cell culture supernatant.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3. from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
Concentration of sCDH6 in cell culture supernatant.